WATCH: Trump administration officials announce PTSD research funding for psychedelic drug ibogaine

In a significant development, incoming Democratic leaders of essential committees have signaled their intention to investigate the mutually beneficial drug pricing agreements between pharmaceutical companies and the Trump administration. These deals, which are anticipated to be a primary health care oversight concern for Democrats upon gaining the majority in January, have reportedly prompted additional companies to sign agreements with the Trump administration since earlier this year.

The Senate Finance Committee and the House Energy and Commerce's Ways and Means, as well as Education and Labor committees, have been proactive in their pursuit of transparency. They have requested that these companies disclose the specifics of their arrangements, which tie Medicaid drug prices to those in comparable countries. Recently, a fresh batch of letters was dispatched to all 27 entities involved, according to a congressional source privy to the matter. Endpoints News broke the news of these new requests, which is being reported in detail on STAT+.